Based on the investor presentation available from their web, their current 6 products (excl. DSC127) have a revenue potential between 58 to 145 mio USD. This alone should make them very profitable.
If adding DSC127, it could go up to between 158 to 395 mio USD. (all based in DSCI's own estimate).
If those numbers become reality, this is a 10+ USD share in the long-run, and possibly much higher still.
Next milestone will be the phase II results late summer/fall 2010, and any collaboration with a bigger name company.
I'll expect the price to hang around 40 to 80 cents for at least several more months, and I'll take the opportunity to buy more on the dips. My plan is to get as close as possible to 50.000 shares, but to spend no more than 27500 USD.
Thereafter I'll lay back and let the future take its run.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM